<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357591</url>
  </required_header>
  <id_info>
    <org_study_id>IDEG020301</org_study_id>
    <nct_id>NCT00357591</nct_id>
  </id_info>
  <brief_title>Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation</brief_title>
  <official_title>MOMENTUM: Multicenter Trial of the Orqis Medical CRS for the Enhanced Treatment of CHF Unresponsive to Medical Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orqis Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orqis Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Company's proprietary products are based on Orqis Medical's hypothesis, supported by&#xD;
      early clinical data, that increasing and maintaining continuous blood flow in the descending&#xD;
      aorta, known as continuous aortic flow augmentation or CAFA, improves hemodynamics in heart&#xD;
      failure patients. The clinical impact of the hemodynamic improvement is currently being&#xD;
      evaluated to determine the effects of CAFA on stopping or reversing the progression of heart&#xD;
      failure through three physiological effects:&#xD;
&#xD;
        -  VASCULAR - Reducing systemic vascular resistance&#xD;
&#xD;
        -  RENAL - Improving renal function&#xD;
&#xD;
        -  CARDIAC - Reducing cardiac workload&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Projected neutral significance for primary composite efficacy endpoint.&#xD;
  </why_stopped>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Anticipated">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alive, Number of days out of the hospital, not on mechanical assistance over 35 day period.</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Aortic Flow Augmentation</intervention_name>
    <description>1.0-1.5 lpm augmented blood flow</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients hospitalized due to decompensated heart failure who require IV inotropic&#xD;
             and/or vasodilator and diuretic therapy&#xD;
&#xD;
          2. Patients receiving appropriate medical therapy for heart failure, defined as ACE&#xD;
             inhibitors and beta blockers (all unless not tolerated or contraindicated) and&#xD;
             diuretics, for 1 month prior to study entry&#xD;
&#xD;
          3. For at least 24 hours prior to inclusion into the study, the patient should be treated&#xD;
             with a minimum dose of the following: dobutamine 2.5μg/kg/min or milrinone&#xD;
             0.3μg/kg/min or dopamine 5μg/kg/min. or nesiritide 0.01μg/kg/min or nitroglycerin 0.3&#xD;
             µg/kg/min or nitroprusside 0.3 µg/kg/min or a combination of any of these agents, with&#xD;
             diuretic therapy. Doses of the above stated medications should be stable for 6 hours&#xD;
             prior to inclusion into study. An increase in this dosage within the first 8 hours&#xD;
             after enrollment is determined by the attending physician to be unlikely and the&#xD;
             following definition of &quot;not responding adequately to IV inotropic and/or vasodilator&#xD;
             and diuretic therapy&quot; is exhibited:&#xD;
&#xD;
               -  PCWP is ≥ 20 mmHg at time of randomization and PCWP was ≥ 18 mmHg continuously&#xD;
                  for 24 hours or PCWP ≥ 20 mmHg continuously for 12 hours prior to randomization.&#xD;
&#xD;
               -  Cardiac Index &lt; 2.4 L/min/m2&#xD;
&#xD;
               -  There is evidence for abnormal renal function and/or diuretic resistance defined&#xD;
                  as: Serum creatinine &gt; 1.2 mg/dL or Diuretic dosage of intravenous Furosemide ≥&#xD;
                  120 mg daily, or equivalent&#xD;
&#xD;
          4. LVEF &lt; 35%&#xD;
&#xD;
          5. Male or female 18-90 years of age&#xD;
&#xD;
          6. If female, no child-bearing potential or negative pregnancy test&#xD;
&#xD;
          7. Written informed consent&#xD;
&#xD;
          8. Willingness to participate in required follow-up exams&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute Q-wave myocardial infarction within past 7 days&#xD;
&#xD;
          2. Post cardiotomy shock within past 30 days&#xD;
&#xD;
          3. Cardiac surgery within past 14 days&#xD;
&#xD;
          4. Bridge to transplant&#xD;
&#xD;
          5. History of severe COPD as defined as FEV1 &lt; 1.0 liter&#xD;
&#xD;
          6. History of malignant arrhythmias defined as either:&#xD;
&#xD;
               -  sustained ventricular tachycardia &gt; 15 beats or more in length, not associated&#xD;
                  with a correctable cause, within the preceding 3 months, unless the patient&#xD;
                  presently has an implantable cardiac defibrillator.&#xD;
&#xD;
               -  history of ventricular fibrillation or sudden death, unless the patient presently&#xD;
                  has an implantable cardiac defibrillator&#xD;
&#xD;
          7. Patients implanted with a resynchronization device within the previous 14 days or if&#xD;
             there is a possibility of implant within 60 days following randomization&#xD;
&#xD;
          8. Systolic pressure &lt;80 mmHg&#xD;
&#xD;
          9. Requiring cardiopulmonary support type devices&#xD;
&#xD;
         10. Platelets &lt; 50,000/mm3 or other evidence of coagulopathy, INR greater than 1.5 in the&#xD;
             absence of anticoagulation therapy.&#xD;
&#xD;
         11. Infection (WBC ≥ 12.5 x 103/ml, and or temperature ≥ 100.5°F/38°C)&#xD;
&#xD;
         12. History of cerebral vascular accident (CVA) or transient ischemic attacks (TIA) within&#xD;
             the last 3 months&#xD;
&#xD;
         13. Unwilling or unable to receive blood transfusion&#xD;
&#xD;
         14. Inability to undergo treatment with heparin&#xD;
&#xD;
         15. Patients on dialysis or serum creatinine &gt; 4.0 mg/dl&#xD;
&#xD;
         16. Primary liver disease with bilirubin, SGOT, or SGPT &gt; 4X upper limit of normal&#xD;
&#xD;
         17. Life expectancy from other disease &lt; 12 months&#xD;
&#xD;
         18. Patients who are active on the cardiac transplantation waiting list, unless there is a&#xD;
             documented reason (large body habitus, highly sensitized, O blood group) to anticipate&#xD;
             that transplant is unlikely within the subsequent 65 days.&#xD;
&#xD;
         19. Symptomatic patent foramen ovale or intracardiac shunt&#xD;
&#xD;
         20. Patients diagnosed with clinically significant peripheral vascular disease, defined as&#xD;
             absent pedal pulse or signs or symptoms of limb ischemia, including a history of&#xD;
             intermittent claudication&#xD;
&#xD;
         21. Patients with amyloidosis, thyroid induced heart failure, high output failure&#xD;
             secondary to an arterio-venous fistula, and significant uncorrected primary valvular&#xD;
             disease (with the exception of mitral regurgitation believed secondary to LV&#xD;
             dilatation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry H Greenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://healthcare.utah.edu/internalmedicine/clinicaltrials/current/trials/momentum.html</url>
    <description>MOMENTUM Trial Website</description>
  </link>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>December 24, 2009</last_update_submitted>
  <last_update_submitted_qc>December 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Irene Parker/VP Regulatory Affairs</name_title>
    <organization>Orqis Medical Corporation</organization>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Acute Decompensation</keyword>
  <keyword>Chronic Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

